The human brain operates on a dynamic equilibrium between neurotransmitters and metal ions [1]. Dopamine, a major catecholamine neurotransmitter, regulates movement, reward processing, motivation, and executive function [2]. Copper is an essential trace metal that participates in neurotransmitter synthesis, mitochondrial respiration, antioxidant defense, synaptic signaling, and iron homeostasis [3]. Although they serve different roles, copper and dopamine are tightly interconnected through multiple biochemical pathways. Copper supports the enzymes needed for dopamine metabolism (synthesis & degradation) [4]. Copper acts as a cofactor for dopamine β-hydroxylase, the enzyme responsible for the conversion of dopamine to norepinephrine [5]. Copper is also involved in the structural integrity and function of MAO, the primary enzyme responsible for degrading dopamine into metabolites like DOPAC [6]. Beyond enzymatic regulation, copper and dopamine interact directly at the molecular level, where dopamine binds with free Cu(II) ions to form redox-active complexes that catalyze dopamine oxidation, leading to the generation of reactive oxygen species (ROS), quinones, mitochondrial dysfunction, α-synuclein aggregation, and subsequent ferroptotic/cuproptotic neuronal stress [7].

The disruption of copper–dopamine equilibrium plays a critical role in the pathogenesis of several neurodegenerative disorders, as dopaminergic neurons are particularly vulnerable to disturbances in copper homeostasis. Both elevated and deficient levels of free or protein-bound copper ions in blood and other biological fluids can alter dopamine concentration and neurotransmission, potentially leading to neurological and cognitive dysfunction [8]. Copper transport into the brain is mediated by specific proteins such as CTR1 and ATP7A, which are highly active in dopamine-rich regions like the substantia nigra, an area especially susceptible to metal ion imbalance [9]. Intracellular copper distribution is further regulated by proteins including ATP7A, ATP7B, ATOX1, CCS, and COX17, and dysfunction in these transport or chaperone systems can directly impair dopamine-related neurochemical pathways [10,11]. In Menkes disease, defective copper transport reduces norepinephrine synthesis due to insufficient copper availability, whereas in Wilson’s disease, excessive copper accumulation induces oxidative and mitochondrial stress in dopaminergic neurons [12]. Similarly, in Parkinson’s disease and Alzheimer’s disease, copper-induced oxidative stress, mitochondrial dysfunction, and abnormal aggregation of α-synuclein and tau proteins contribute significantly to neuronal degeneration [13,14]. These findings collectively highlight the pathological significance of copper–dopamine interactions in neurodegenerative diseases [15].

Emerging evidence further indicates that copper–dopamine dysregulation converges with pathological mechanisms common to stroke and neurodegenerative diseases, including oxidative stress, neuroinflammation, blood–brain barrier disruption, excitotoxicity, and immune imbalance [16]. Since copper imbalance and dopamine oxidation amplify reactive oxygen species generation and inflammatory signaling, integrated monitoring of copper–dopamine dynamics may provide valuable insights into broader neuroimmune and neurovascular dysfunction underlying neurodegenerative progression [17].

Due to the distinct redox behaviors by both copper and dopamine, their interaction produces quantifiable electrochemical signals, making them promising targets for next-generation advance biosensors [18]. Simultaneous monitoring of copper–dopamine dynamics, rather than assessing or quantifying each analyte in isolation, enables the identification of more precise early biomarkers of neurodegeneration, track therapeutic responses, and support the development of real-time neurochemical monitoring platforms [19]. Elucidating this strongly interconnected biochemical relationship provides a robust scientific foundation for designing future biosensors that can detect subtle fluctuations in copper and dopamine concentrations prior to the onset of clinical symptoms, enabling earlier diagnosis, personalized therapeutic approaches, and improved neuroprotective strategies [20,21].

Most current biosensing technologies are primarily limited to single-analyte detection, particularly for dopamine or copper independently. Dopamine biosensing has advanced through modified carbon electrodes, nanocomposite coatings, metal–organic frameworks, and enzyme-mimetic catalytic platforms, whereas copper detection has largely relied on stripping voltammetry, ligand-functionalized electrodes, and metal-chelating nanomaterials for ultra-trace environmental monitoring [22,23]. Despite these advancements, very few approaches are designed to monitor the direct biochemical interplay between copper and dopamine in biological fluids, which is increasingly recognized as crucial for understanding and diagnosing neurodegenerative disorders. Conventional neurological assessment methods, including MRI, PET imaging, cerebrospinal fluid analysis, electrophysiological recordings, and genetic profiling, often remain expensive, invasive, or incapable of providing continuous biochemical monitoring [24]. In contrast, integrated copper–dopamine biosensing platforms offer the potential for real-time, portable, and clinically accessible neurochemical assessment.

The strong redox coupling between copper ions and dopamine provides a unique opportunity for dual-analyte sensing. Copper significantly influences dopamine oxidation behavior, while dopamine itself can act as a sensitive probe for fluctuations in copper concentration through metal binding and redox interactions. This bidirectional interaction generates distinct electrochemical fingerprints that can improve sensing sensitivity, selectivity, and biological relevance. Recent proof-of-concept studies employing Au@Cu-MOF systems, dopamine-functionalized nanoparticles, and multiplexed electrochemical interfaces have already demonstrated successful simultaneous detection of copper and dopamine under physiological conditions [25,26]. Sensor designs that utilize this two-way interaction allow concurrent measurement leading to improved sensitivity, selectivity, and biological relevance. Integrating copper and dopamine detection within a single sensing platform therefore offers a promising route for next-generation neuronal health monitoring by translating metal–neurotransmitter interactions into clinically diagnostic output. Such integrated sensing strategies may enable early identification of oxidative stress, redox imbalance, mitochondrial dysfunction, and copper-dependent neuronal injury associated with neurodegenerative progression and cuproptotic activity [27].

However, simultaneous copper–dopamine biosensing remains analytically challenging due to overlapping oxidation potentials of dopamine, copper, and other endogenous redox-active species such as uric acid and ascorbic acid [28]. Additional complications arise from catalytic interference, changes in electrode surface chemistry, protein fouling, pH fluctuations, and the formation of polymeric dopamine oxidation products under dynamic biological conditions [29,30]. Although advanced platforms such as enzyme-functionalized electrodes, graphene field-effect transistor sensors, microfluidic electrochemical chips, and implantable neural probes have shown promising sensitivity, many still suffer from signal drift, limited selectivity, biofouling, and poor long-term stability in complex biological matrices [31,32].

To address the existing limitations in simultaneous copper–dopamine biosensing, significant efforts are now focused on the development of advanced electrode materials such as graphene derivatives, MXene hybrids, nanoporous metal oxides, and copper-modulated catalytic surfaces [33]. These materials provide enhanced electron-transfer kinetics, reduced surface fouling, and improved molecular recognition toward catechol groups and copper ions, thereby enabling more reliable multiplexed sensing on a single platform [34]. Their integration into microelectrode arrays and flexible neural interfaces further supports the possibility of real-time, in vivo monitoring of copper–dopamine dynamics [35].

Building upon these advances, miniaturized wearable technologies including microneedle-based sensors and soft neural implants are emerging as the next generation of neurochemical monitoring systems [36]. Such devices enable continuous and minimally invasive assessment of copper–dopamine interactions in both clinical and personal healthcare settings [37]. Coupled with biointegrated electronics and healthcare Internet-of-Things (IoT) ecosystems, wearable biosensors may facilitate remote neurochemical surveillance, early intervention, and personalized therapeutic management [38].

The future of copper–dopamine biosensing is expected to move toward multimodal and intelligent sensing architectures that combine electrochemical, optical, and impedance-based detection with machine-learning-assisted signal analysis [39]. Computational models trained on simultaneous copper–dopamine datasets could enable predictive biomarker identification, disease-stage assessment, anomaly detection, and personalized therapeutic evaluation for neurodegenerative disorders such as Parkinson’s disease, Wilson’s disease, and Alzheimer’s disease [40]. Integration of artificial intelligence with wearable neurochemical monitoring platforms may therefore establish a foundation for predictive neurological healthcare and long-term remote patient management [41].

Ultimately, the translation of laboratory-scale biosensors into clinically viable and long-term implantable systems represents a major future direction in neurochemical diagnostics. Continuous monitoring of copper–dopamine fluctuations may support early detection of neurodegenerative disorders before irreversible neuronal damage occurs, while also assisting clinicians in disease stratification, therapeutic monitoring, and personalized treatment planning [42,43]. However, despite their significant clinical potential, continuous neurochemical monitoring technologies also raise important ethical and privacy concerns related to patient consent, long-term data security, algorithmic bias, and psychological dependence on continuous monitoring systems [44]. Therefore, the responsible integration of wearable neurochemical biosensors into healthcare frameworks will require robust regulatory oversight, transparent data governance, and clinically validated interpretation protocols [45].

The copper–dopamine interaction is vital for brain health, while persistent disruption of this homeostasis can accelerate oxidative neuronal injury, neuroinflammation, mitochondrial dysfunction, and progressive neurodegeneration. Such imbalance is strongly associated with neurodegenerative disorders including Parkinson’s disease and Alzheimer’s disease, highlighting the need for early biochemical intervention and reliable monitoring strategies. Emerging biosensor technologies that monitor both elements in real time offer new opportunities for early diagnosis and personalized treatment, paving the way for proactive neurological care. Advanced biosensing platforms capable of tracking copper–dopamine dynamics may provide early biochemical fingerprints of emerging processes such as cuproptosis, offering new opportunities for predictive diagnostics and early intervention in neurodegenerative diseases. The ongoing evolution of miniaturized, wearable, and multimodal biosensors is expected to transform neurological healthcare, shifting the focus towards proactive and preventive care strategies.